Dr Reddy's Q2 Results: Net profit jumps 30% to Rs 992 crore, beats Street estimates

Its EBITDA margin stood at 27 percent in the September quarter, as against 25.9 percent a year ago.

Analysts had estimated Dr Reddy's Laboratories' EBITDA at Rs 1,178.9 crore and EBITDA margin at 22.8 percent.

"I am pleased with the improvement in the financial performance across our businesses. While we continue to strengthen our core businesses of generics and APls, we are also making investments in our long-term growth drivers and deeper innovation capabilities," said GV Prasad, Co-Chairman and MD, Dr Reddy's Laboratories.

The global generics business saw growth of 19 percent. Revenue from the North American unit rose three percent on year. The European business rose 10 percent.

Dr Reddy's posted 25 percent year-on-year growth in its India business. The emerging markets unit saw growth of 50 percent.

Dr Reddy's shares clocked sharp gains after the earnings announcement. The stock traded 4.5 percent higher at Rs 4,780 apiece on BSE. The headline Sensex index was down 0.8 percent amid highly volatile trade.